NEW YORK ─ Bio-Techne expects its acquisition of molecular diagnostics firm Asuragen will soon contribute valuable expertise and add to year-over-year revenue growth in its diagnostics business segment, Bio-Techne's CEO said.
NEW YORK ─ Bio-Techne expects its acquisition of molecular diagnostics firm Asuragen will soon contribute valuable expertise and add to year-over-year revenue growth in its diagnostics business segment, Bio-Techne's CEO said.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.